Cambridge NeuroScience Inc. announced Friday it isdiscontinuing development of Ectapram as an adjunct toelectroconvulsive therapy (ECT).

A pilot Phase II/III trial of the compound, in-licensed fromWarner Lambert, did not show enough clear-cut superioritycompared with ECT treatment alone to warrant continueddevelopment, the company said.

Cambridge NeuroScience (NASDAQ:CNSI) of Cambridge, Mass.,announced in March 1992 it planned two trials of 100 patientseach, but Elkan Gamzu, company president, told BioWorld thatthe second trial was not carried out.

The company anticipates it will save $10 million in researchand development resources over the next 18 months, whichcan be redirected to internally developed proprietary products,including a more aggressive clinical trail later this month forthe company's lead compound, stroke treatment Cerestat.

Ectapram (pramiracetam) had been explored for its potential toreduce memory loss and confusion resulting from ECTtreatments.

Cambridge Neuro's stock fell $2 a share on Friday to close at $6.-- Nancy Garcia

(c) 1997 American Health Consultants. All rights reserved.